US FDA approves at-home use of agitation drug

lgalmi


The US Food and Drug Administration on Monday approved at-home use of BioXcel Therapeutics’ drug, Igalmi, ​for agitation associated with schizophrenia or bipolar ‌disorder.

The company last month completed the sale of nearly all its assets, including Igalmi, to a unit of ​Teva Pharmaceuticals.

The approval expands Igalmi’s use to outpatient settings without supervision of a healthcare provider, where there are no FDA-approved options available, Teva said.

Teva said it will announce commercialization plans for the drug’s at-home use at a later date. Igalmi, chemically known as dexmedetomidine, was approved as an orally dissolving film in April 2022 to treat agitation associated with schizophrenia or bipolar disorder in adults with medical supervision.

Schizophrenia is a mental health disorder that causes delusions, hallucinations and disorganized thinking. Bipolar disorder, also a mental health condition, causes strong mood swings. Agitation associated with schizophrenia and bipolar disorder affects 25% to 40% of patients across these conditions, Teva said.

About BXCL501

Outside of its approved indication by the U.S. Food and Drug Administration as IGALMI® (dexmedetomidine) sublingual film, BXCL501 is an investigational proprietary, orally dissolving film formulation of dexmedetomidine, a selective alpha-2 adrenergic receptor agonist. BXCL501 is under investigation by BioXcel Therapeutics for the acute treatment of agitation associated with Alzheimer’s dementia and for the acute treatment of agitation associated with bipolar I or II disorder or schizophrenia in the at-home setting. The safety and efficacy of BXCL501 for these investigational uses have not been established. BXCL501 has been granted Breakthrough Therapy designation by the FDA for the acute treatment of agitation associated with dementia and Fast Track designation for the acute treatment of agitation associated with schizophrenia, bipolar disorders, and dementia.

About IGALMI® (dexmedetomidine) sublingual film

IGALMI® (dexmedetomidine) sublingual film is a prescription medicine, administered under the supervision of a health care provider, that is placed under the tongue or behind the lower lip and is used for the acute treatment of agitation associated with schizophrenia and bipolar disorder I or II in adults. The safety and effectiveness of IGALMI has not been studied beyond 24 hours from the first dose. It is not known if IGALMI is safe and effective in children.



Source link

متعلقہ پوسٹ